Lyell Immunopharma, Inc. (LYEL)
12.26
-0.62
(-4.81%)
USD |
NASDAQ |
Sep 10, 15:23
Lyell Immunopharma Profit Margin (Quarterly) : -1.12M% for June 30, 2026
Profit Margin (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -1.12M% |
| March 31, 2026 | -1.21M% |
| December 31, 2025 | -2.35M% |
| September 30, 2025 | -259.0K% |
| June 30, 2025 | -533.6K% |
| March 31, 2025 | -745.6K% |
| December 31, 2024 | -1.74M% |
| September 30, 2024 | -131.1K% |
| June 30, 2024 | -352.4K% |
| March 31, 2024 | -2.02M% |
| December 31, 2023 | -407.2K% |
| September 30, 2023 | -203.4K% |
| June 30, 2023 | -236.6K% |
| Date | Value |
|---|---|
| March 31, 2023 | -103.0K% |
| December 31, 2022 | -17.35% |
| September 30, 2022 | -2.34M% |
| June 30, 2022 | -101.6% |
| March 31, 2022 | -12.32K% |
| December 31, 2021 | -2.97K% |
| September 30, 2021 | -1.77K% |
| June 30, 2021 | -2.38K% |
| March 31, 2021 | -2.25K% |
| December 31, 2020 | -1.68K% |
| September 30, 2020 | -3.34K% |
| June 30, 2020 | -3.23K% |
| March 31, 2020 | -2.33K% |
Profit Margin Definition
Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.
Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Profit Margin (Quarterly) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | -237.8% |
| Oncolytics Biotech, Inc. | -- |
| Sangamo Therapeutics, Inc. | -2.15K% |
| Sarepta Therapeutics, Inc. | -1.22% |
| Anixa Biosciences, Inc. | -- |
Profit Margin (Quarterly) Related Metrics
| Return on Equity | -89.79% |
| Return on Assets | -69.20% |
| Return on Invested Capital | -76.23% |
| Gross Profit Margin (Quarterly) | -55.45K% |
| Operating Margin (Quarterly) | -1.23M% |
| Return on Net Operating Assets | -450.7% |